CRISPR/Cas9-Based Engineering of the Epigenome.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 28985525.
- Also identified by DOI 10.1016/j.stem.2017.09.006 and PMC identifier 6205890.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Determining causal relationships between distinct chromatin features and gene expression, and ultimately cell behavior, remains a major challenge. Recent developments in targetable epigenome-editing tools enable us to assign direct transcriptional and functional consequences to locus-specific chromatin modifications. This Protocol Review discusses the unprecedented opportunity that CRISPR/Cas9 technology offers for investigating and manipulating the epigenome to facilitate further understanding of stem cell biology and engineering of stem cells for therapeutic applications. We also provide technical considerations for standardization and further improvement of the CRISPR/Cas9-based tools to engineer the epigenome.
Medical subject headings
- CRISPR-Cas Systems
- Epigenesis, Genetic
- Genome